Valuation: Grace Therapeutics, Inc.

Market Cap 56.51M 40.11M 35.18M 32.52M 29.91M 3.87B 57.4M 389M 152M 1.9B 151M 147M 6.52B P/E 2027 *
-4.64x
P/E 2028 * -4.41x
Enterprise Value 56.51M 40.11M 35.18M 32.52M 29.91M 3.87B 57.4M 389M 152M 1.9B 151M 147M 6.52B EV / Sales 2027 *
-
EV / Sales 2028 * 7.21x
Free-Float
74.27%
Yield 2027 *
-
Yield 2028 * -
1 day-1.62%
1 week-0.82%
Current month+7.05%
1 month+2.10%
3 months-47.17%
6 months-33.42%
Current year-29.77%
1 week 2.33
Extreme 2.33
2.54
1 month 2.08
Extreme 2.0782
2.58
Current year 1.79
Extreme 1.79
5.18
1 year 1.79
Extreme 1.79
5.18
3 years 1.72
Extreme 1.72
5.18
5 years 1.72
Extreme 1.72
27.07
10 years 1.72
Extreme 1.72
161.11
Manager TitleAgeSince
Chief Executive Officer 54 03/04/2023
Director of Finance/CFO 54 04/01/2024
Chief Tech/Sci/R&D Officer 64 07/05/2023
Director TitleAgeSince
Chairman 57 -
Director/Board Member 54 03/04/2023
Director/Board Member 59 09/10/2023
Date Insider Type Main position Quantity % Market Cap.
12/01/26 Option

Director

10,000 0.0646%
12/01/26 Option

Director

10,000 0.0646%
12/01/26 Option

Director

10,000 0.0646%
Change 5-day change 1-year change 3-year change Capi.($)
-1.62%-0.82%-27.68%-4.33% 40.2M
+0.21%-1.34%+53.17%+60.65% 53.83B
+5.37%+0.75%+50.39%+83.03% 52.1B
-1.20%-7.43%+4.35%+406.96% 23.48B
+0.74%+0.73%-16.23%-15.55% 23.13B
+3.46%+0.79%+34.01%-4.47% 19.36B
-1.18%-1.15%+30.12%-32.02% 17.56B
-1.67%-8.56%+163.95%+284.69% 15.2B
+3.62%-2.42%+29.70%+663.64% 14.83B
-0.70%-1.72%+24.87%+184.19% 14.06B
Average +0.70%-2.11%+34.66%+162.68% 23.36B
Weighted average by Cap. +1.48%-2.34%+41.45%+140.82%

Financials

2027 *2028 *
Net sales - 7.83M 5.56M 4.88M 4.51M 4.15M 536M 7.96M 53.85M 21.06M 263M 20.89M 20.44M 904M
Net income -12.76M -9.06M -7.94M -7.34M -6.75M -874M -12.96M -87.71M -34.31M -428M -34.03M -33.29M -1.47B -20.46M -14.52M -12.74M -11.78M -10.83M -1.4B -20.78M -141M -55.03M -686M -54.58M -53.39M -2.36B
Net Debt - -
Logo Grace Therapeutics, Inc.
Grace Therapeutics, Inc. is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its novel drug delivery technologies have the potential to improve the performance of marketed drugs by achieving faster onset of action, and reduced side effects. Its lead clinical asset, GTx-104, is an intravenous infusion targeting aneurysmal Subarachnoid Hemorrhage (aSAH), a rare and life-threatening medical emergency in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull. The nanoparticle technology of GTx-104 facilitates aqueous formulation of insoluble nimodipine for a standard peripheral IV infusion. Its other pipeline includes GTX-102, which is targeted as the first potential therapy for the treatment of ataxia-telangiectasia (AT) in a pediatric population and GTx-101, which is a topical administration via a bioadhesive, film-forming polymer, for the treatment of pain associated with postherpetic neuralgia.
Employees
5
Date Price Change Volume
20/07/26 US$2.430 -1.62% 104,821
17/07/26 US$2.470 +2.49% 122,539
16/07/26 US$2.410 -0.82% 279,801
15/07/26 US$2.430 -1.22% 116,881
14/07/26 US$2.460 +1.23% 153,267
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
3.416CAD
Average target price
8.447CAD
Spread / Average Target
+147.25%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GRCE Stock